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Abstract: 
Background: Polycystic ovarian syndrome (PCOS) is the most common cause of ovulatory 
infertility with an endocrine origin. An alternative therapy for PCOS is complementary medicine 
(CM), with herbal medicine becoming the most popular during the past ten years. The fennel plant 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 2 
 
(Foeniculum Vulgare Mill) belongs to the flowering plant of the fennel Apiaceae family. It is a 
medicinal plant that is commonly recommended by practitioners of Iranian traditional medicine 
for ovarian or unknown infertility in women because it has an estrogenic effect.  The effects of 
fennel (FOEVU: Foeniculum vulgare Mill essence of fennel seeds) on PCOS has yet to be 
investigated. Therefore, the main objective of our study was to investigate and evaluate the effects 
of fennel essential oil capsules on PCOS symptoms. 
Subjects and Methods: This study was a double-blinded, randomized controlled study. Our 
subjects were thirty female students who were selected from the age range of 20-35 and met the 
Rotterdam diagnostic criteria for PCOS. The subjects were randomly assigned to two groups: 
fennel (study) and placebo (control). The ultrasonography assessments, body mass index, 
biochemical, and hirsutism variables were measured individually before and after three months 
usage of the fennel and placebo as our main outcome measurements. The comparison between the 
quantitative data obtained for the two studied groups was carried out using the Man-Whitney and 
chi-square tests. 
Results: The comparison of menstruation cycle, hirsutism, BMI, biochemical, and ultrasonography 
measurements revealed that the interventions did not cause significant differences in the two 
groups, except in the dehydroepiandrosterone sulphate (DHEAS)  and ovarian volume (p<0.05). 
Conclusion:  Fennel was not effective in alleviating the ovarian cyst symptoms in polycystic 
women but since the sample size calculation in our small study was based on very large effect 
sizes, the study might not be powered enough to detect smaller effects. 
 
Key words: fennel, PCOS, treatment, polycystic ovarian syndrome 
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BACKGROUND: 
Polycystic ovarian syndrome (PCOS) is of endocrine origin and is the most common cause of 
ovulatory infertility. It is also a major factor for metabolic syndrome, cardiovascular disease, and 
type 2 diabetes mellitus. Clinical symptoms of PCOS such as acne, hirsutism, obesity, and alopecia 
can also cause psychological problems, especially for adolescents (Beltadze and Barbakadze, 
2015). PCOS is usually associated with hormonal abnormalities through changes in the 
concentrations of the luteinizing hormone (LH), prolactin, estrogen, and serum androgens 
(testosterone and androstenedione) (Jalilian et al., 2015). Two principal components to clinically 
diagnose this syndrome are menstrual dysfunction and clinical or laboratory hyperandrogenism, 
(Taghavi and Fatemi 2008). Hormonal measurements indicate that many women with PCOS have 
an increased LH/FSH ratio. Therefore, the ratio of 2 to 1 and sometimes 2.5 to 1 of LH/FSH is 
considered as the biochemical measurement for diagnosing this disease (Jalilian et al., 2015). 
In addition, the economic  and  psychological burden of this syndrome is potentially significant 
for public providers, health caregivers and patients (Azziz, 2005; Barry, 2011). Despite the 
potential public health impact of PCOS, estimates regarding its prevalence are surprisingly scarce, 
with a wide range from 2.2% to as high as 26% (Ramezani Tehrani et al., 2011). Moreover, the 
prevalence of this syndrome has been estimated among different populations in various studies 
(Mehrabian et al., 2011). The prevalence of PCOS based on the National Institute of Child Health 
and Human Development of the U.S has been reported as 6.8%. However, based on the Rotterdam 
diagnostic criteria it has been reported as 19.5% and based on ultrasound reports it has been 
reported as 4.41% (Jalilian et al., 2015).  
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Weight loss and metformin administration have been shown to improve hyperandrogenic signs 
and symptoms of PCOS, and this may be due to lowered androgen levels. Others have 
demonstrated that changing dietary habits, even without any significant weight loss, may also 
improve endocrine features and reproductive functions in this group of patients (Firouzabadi et al., 
2012). The Rotterdam diagnostic criteria was presented by the Fertility and Embryology 
Association of Europe and the America Fertility Society in the Rotterdam Conference in 2003, and 
they have determined that two of these three criteria (oligoovulation, hyperandrogenism, or  the 
presence of polycystic ovaries on pelvic ultrasound) as a criteria for diagnosing PCOS 
(Rahmanpour et al., 2009). 
Complementary medicine (CM) is an alternative or natural therapy that includes taking dietary 
supplements such as herbs like cinnamon (Wang et al., 2007), vitamins such as vitamin D (Irani 
et al., 2017), minerals  such as chromium (Fazelian et al., 2017), or nutritional supplements such 
as fish oil (Sadeghi et al., 2017). The use of these treatments by women has increased during the 
last ten years (Smith et al., 2013), with rates of use ranging between 26% and 91% (Bishop et al., 
2011). A popular form of complementary medicine is herbal medicine. Herbal medicines are 
known to contain pharmacologically active constituents with physiological effects on the female 
endocrine system, and have been positively associated with reduced incidences of breast cancer, 
osteoporosis, and cardiovascular disease (Grant and Ramasamy 2012). 
The use of plants accompanied by synthetic drugs, on the other hand, is also effective in treating 
certain diseases. In Iran, herbal remedies (such as fennel, chamomile, and marigold) are 
traditionally used for treating dysmenorrhea. Both the seed and extract of fennel (Foeniculum 
vulgare Mill), which is an umbelliferous plant, are commonly used by the many tribes of Iran and 
are appetizing, useful for digestive and menstrual disorders, and are diuretic, anti-spasmodic, 
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laxative (Nasehi et al., 2013) and lactogenic (Ghasemi et al., 2015). Fennel has also been 
traditionally used for treating ovarian cysts (Bokaie et al., 2013). This plant has an estrogenic 
effect, and has been shown to have anti-inflammatory, anti-spasmodic, analgesic, carminative, and 
expectorant effects. Also, because of its anti-oxidative effects it is also useful for nervous disorders 
(Delaram et al., 2011). 
The fennel plant (Foeniculum vulgare Mill) belongs to the flowering plant of the fennel Apiaceous 
family. Foeniculum vulgare seeds contain volatile oil composed largely of anethole, which is a 
phytoestrogen, as well as fenchone, estragole, 1,8-cineole (eucalyptol), and other constituents 
(Bajan et al., 2011), and is helpful in treating colic as well as having a slight pain-reducing 
potentiality for dysmenorrhea (Bokaie, Farajkhoda et al. 2013). Fennel is also useful for weight 
loss and can affect the BMI (Abdelaaty et al., 2012). It is believed that this is one way fennel helps 
in treating PCOS, because weight reduction is an important treatment target in individuals who 
have PCOS associated with obesity (Lass et al., 2011). 
The decrease of androgen levels, especially testosterone, is another way to treat PCOS. Mirseyed 
et al. evaluated the effects of fennel in male rat spermatogenesis and showed a significant 
decreasing trend in terms of testosterone hormones such as LH and FSH (Mirseyed et al., 2008). 
Another study done on the aqueous extract of fennel seed showed the beneficial effect on renal 
function in PCOS rats (Zeraati et al., 2014). 
To the authors’ knowledge no similar study has been carried out to evaluate the effects of fennel 
on PCOS. Therefore, the main objective of this study was to investigate the effects of fennel on 
biochemical levels, hirsutism, and menstruation cycles of Iranian women diagnosed with PCOS. 
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Subjects and Methods:  
 
Study design: This was a double-blinded, single-center, and prospective randomized controlled 
parallel study conducted at the Jahrom University of Medical Sciences, Iran. This study was 
registered in the Iranian registry of clinical trials. (Registration number: 
IRCT2016040427207N1). The scientific review committee and institutional ethics committee of 
the Jahrom University of Medical Sciences approved the present study. 
Participants: Female students were asked if they had clinical signs of hyperandrogenism or 
oligomenorrhea. 
Sample size estimation:  There was no previous comparable study on which to base data for a 
sample size calculation. To estimate an acceptable sample size, the following formula was used: 
a significance level of 0.05, a power level of 0.80, an effect size of 1.5 based on blood 
testosterone changes and SD=2. The minimum sample size for this study was 15 in each group. 
they were selected by consecutive sampling from students aged 20-35 who met the study's 
inclusion criteria. 
Procedure: The inclusion criteria of the subjects were based on the Rotterdam diagnostic criteria 
for PCOS (Table 1). The exclusion criteria of the subjects were as follows: 
1- Use of any medications to treat PCOS, such as oral hormonal contraceptive during 
treatment. 
2- Rule out other causes such as thyroid dysfunction, pituitary dysfunction and adrenal 
dysfunction. 
3- History of renal or liver disease. 
4- Any allergy to herbal or suspected contraindication to herbal remedies. 
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5- History of major pelvic surgery, seizures, stress factors in the last 6 months, severe 
gastrointestinal disorders, or any diseases that might interfere with the conduct of the study 
or the interpretation of the results.  
Students who satisfied the inclusion criteria and wanted to participate in this trial were asked to 
read and accept the conditions of the study and then sign an informed consent form. Secondly, the 
questionnaires about demographic characteristics, general health, menstrual health, and regularity 
of menstruation were distributed between the selected subjects, and they were asked to fill out the 
questionnaires. The researchers requested the subjects to not use any drugs for the next three 
months. In this study one person from the placebo group discontinued use of the study drug in the 
second month of intervention.  
Randomization and blinding: The manufacturer produced 15 fennel boxes that contain 168 
capsules (46mg) and 15 placebo boxes.  The subjects were requested to use that drug for 12 weeks, 
twice a day (each 12 hours) after meals. Each box was assigned a number from 1 to 30 and each 
participant received one box according to table randomization. The researchers were not informed 
about which of the capsules was the drug or placebo. The subjects and researchers were blinded 
as to whether the given drug was fennel or the placebo. The manufacturer provided a list that 
showed which number assigned to each drug was fennel or the placebo. Only the operator who 
performed the statistical analysis received that list and had information about the numbers and the 
nature of each drug. 
The major components of fennel essential oils included Trans-Anethole, Fenchone and Estragole 
(Methylchavicol). Fennelin soft capsules were supplied by the Barij Essence Pharmaceutical 
Company, Mashhad Ardehal, Kashan, Iran, (http://barijessence.com/en/product/fennelin-softcap/) 
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Foeniculum vulgare Mill essence was produced by distilling the fennel seeds with water vapor 
(Barij Essence Co, Iran produced the drug and placebo) and then for this study they were formed 
into pearl-shaped pills (46 mg). Fennel drug toxicity was assessed in a past study and its safety 
had been reported (Badgujar etal., 2014). The placebo contained 100 mg soya produced by the 
Barij Essence Company. In order to isotropy, each pearl was placed inside a capsule and was 
coded. 
Assessment tools: The following variables were measured on each individual before and after 
three months of drug usage as the main outcome measures (clinical, biochemical and 
ultrasonographic assessment) 
Clinical measurements 
The degree of hirsutism was assessed by using the modified Ferriman-Gallwey method before 
and after the trial. The modified method measures hair growth in these sites: upper lip, chin and 
sides of the face, it has five grades, and the scores range from zero to four for each site (Amiri 
and Ramezani Tehrani 2017).  
Height and weight of the subjects were measured before and after the intervention and BMIs were 
calculated for each of them as follows: BMI (kg/m2) = weight (kg)/ height2 (m2). When the subjects 
used their assigned drugs (fennel or placebo) for a period of three months and then the variables 
were measured, the study was terminated. 
 Duration of menstruation cycles were measured from the first day of one menstrual cycle to the 
first day of the next period according to Patient report. 
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Biochemical measurements 
A venous blood sample was obtained from the studied population to evaluate the changes in the 
level of biochemical factors. Testosterone (reference number: 411712), DEHAS (reference 
number: 1705357), Prolactin(reference number: 725090), TSH (reference number: 411712), FSH 
(reference number: 1655137), and LH (reference number: 1616732) were measured by using the 
enzyme-linked immune sorbent assay method using the Eliza Kit (Monobind Inc., Germany). 
Ultrasonographic assessments 
Ovarian transabdominal sonography was performed for all the subjects at their mid cycle 
(according to the regular menstrual cycle and time intervals of 21-35 days) by one sonographer to 
evaluate the evidence of ovulation, endometrial thickness, right and left ovarian volume, and right 
and left ovarian follicular number. Presence of the dominant follicle >14 mm was considered as 
an evidence of ovulation. 
Statistical analysis 
Obtained data were analyzed using SPSS version 21 (SPSS Inc., Chicago, IL, U.S.A.) software. 
Quantitative variables were presented as the mean ± standard deviation (SD). After using the  
normality test we decided to use the Mann-Whitney and the Wilcoxon tests for  the comparison of 
quantitative data between the two studied groups . P values less than 0.05 were considered 
significant. 
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Results: 
Participant flow: From 30 subjects (15 in the study group and 15 in the control group) who 
entered the study, 29 women completed the study (Figure 1).  
Baseline characteristics: Eleven subjects in the study group (73.3%) and nine subjects in the 
control group (64.3%) were unmarried. The mean ages in this study were 23.60 ± 2.32 years in the 
fennel group and 23.14 ± 2.7 years in the control groups, respectively. 
Primary outcome: 
The degree of hirsutism before the intervention was not significantly different between the two 
groups. The rate of hair growth was not reduced significantly in the two groups after the 
intervention (P > 0.05) (table 2) 
Before the intervention, the Mean ± SD of the BMI in the fennel group was 23.50±5.03, and in the 
placebo group it was 25.27±4.49, although this different was not significant (p=0.290). After the 
intervention, the Mean ± SD of the BMI in the fennel group was 22.97±4.55, and in the placebo 
group it was 25.24±4.64; however, this difference was not statistically significant (p=0.172) 
(Figure 2). 
The duration of the menstruation cycle when compared before (p value = 0.359) and after (p value 
= 0.588) the intervention in the two groups was not significantly different.   
Biochemical measurements (TSH, FSH, LH, DHEAS, PROLACTIN, and free testosterone) before 
the intervention were not significantly different between the two groups. The comparison of the 
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biochemical blood test after the intervention showed that there was no significant difference 
between the two groups (p > 0.05) (table 3). 
Ultrasonography factors (endometrial thickness and ovarian volume) were compared in both 
groups before the intervention and it was shown that endometrial thickness and ovarian volume 
was not different between the placebo and fennel groups; however, the left ovarian follicular 
number (p=0.05) and right ovarian follicular number (p=0.00) were significantly different between 
the two groups. Ultrasonography factors in both groups after the intervention were not significant, 
except for the right and left ovarian follicular number which was significantly different between 
the two groups (Table 4). 
Discussion:   
In this study there was no significant difference between the ovarian cyst symptoms in the fennel 
and control groups, although other studies have shown that fennel might be effective in primary 
dysmenorrhea (Bokaie et al., 2013; Nasehi et al., 2013),  and in decreasing the intensity of infantile 
colic (Alexandrovich et al., 2003).   
To the authors’ knowledge there has been no study that has evaluated the effects of fennel in 
patients with PCOS. Only one animal study has shown that the use of fennel can decrease the 
levels of LH/FSH/testosterone hormones significantly (Modaress Nejad & Asadipour, 2006). 
Aqueous extract of fennel seed has also shown the beneficial effects on renal function in PCOS 
rats (Zeraati et al., 2014).  
In this study, although herbal treatment was not effective in ovarian cyst symptoms, the ovarian 
follicular number before and after the intervention was significantly different, which may be due 
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to trans-abdominal sonographic assessment that is less accurate than trans-vaginal sonography 
measurement. 
Most of the PCOS women with a normal gonadotropin ratio belonged to a group of patients 
suffering from hyperinsulinemia and obesity. Patients with hyperinsulinemia and excess LH 
constitute a selected and distinct subgroup with increased adrenal androgenic activity 
(Banaszewska et al., 2003). Cimicifuga Racemosa was found to decrease the level of  LH (Arentz 
et al., 2014), and another clinical study has shown elevated FSH following treatment with tribulus 
terrestris (Ghosian Moghaddam et al., 2013). 
Although our study showed that there was no significant difference between the effects of fennel 
in the hirsutism score, in another double blind study, idiopathic hirsutism patients were treated 
with creams containing 1% and 2% fennel extract over 12 weeks  with no adverse effects (Javidnia 
et al., 2003). 
The right and left ovarian volume in the fennel group decreased after the intervention, however, 
this difference was not significant. Although Morin-Papunen et al. reported that the mean volumes 
of the right and left ovary did not change after metformin therapy (Morin-Papunen et al., 1998), in 
another research the mean ovarian volume significantly decreased after three months of metformin 
administration (Farimani Sanoee et al., 2011). Similarly, Bayrak et al. showed that one week of 
metformin therapy (850 mg/day) was associated with a significant improvement in PCO 
morphology (Bayrak et al.,  2007). 
In our study, the change of BMI in the two groups before and after the intervention was not 
significant, and this is likely to be related to the use duration of the fennel, which was three months. 
However, based on recent PCOS international guidelines, a six month intervention duration is 
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optimal to reduce the BMI in PCOS women (Teede et al., 2018).Current evidence suggests that 
following a healthy lifestyle that reduces body weight and abdominal fat, can in turn reduce 
testosterone, and improve hair growth and insulin resistance. However, there was no evidence that 
a healthy lifestyle improved cholesterol or glucose levels in women with PCOS (Sirmans and Pate 
2014). In this trial, the level of DHEAS and prolactin were increased insignificantly in the fennel 
group after treatment. Several articles have concluded that PCOS is not associated with the higher 
levels of prolactin measured in daily profiles (Szosland et al., 2015). Milewicz's study has shown 
that a statistically significant correlation was found between the mean prolactin concentrations and 
mean plasma DHEAS concentration (Milewicz, 1984). Regular exercise and calorie restriction are 
known to increase DHEAS production in the primate’s body and this increase is appropriate for 
the general health of the body (Mattison et al., 2003; Moore et al., 2007). Although the effects of 
herbal substances are unknown, some foods such as wild yam, maca root and rose root can increase 
DHEAS levels (Boroch, 2007). 
In this study, fennel was not effective on the length of the menstruation cycle in PCOS women, 
and this could be related to the dosage and duration of treatment. However, the use of another 
phytoestrogen such as vitex has been effective for oligomenorrhea  treatment (Arentz et al., 2014). 
 Some of the limitations of this study were small sample size, poor generalizability and the 
duration of treatment. Thus, we suggest a greater sample size with a longer treatment time for 
future studies to evaluate this herbal drug.  According to budget limitations the effect size which 
the authors used might be too high so the study was unable to detect small differences.  
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In this article satisfaction of subjects was not evaluated. Although our subjects did not inform us 
whether the given drug was fennel or placebo, some of the subjects in the fennel group showed 
satisfaction after the intervention. We recommend that future studies should evaluate the 
satisfaction of PCOS patients who use fennel. If future studies show therapeutic effects and 
satisfaction after using fennel, this herbal drug will be considered for PCOS patients. 
 
Conclusion: 
Fennel was not effective in improving ovarian cyst symptoms in polycystic women. but since the 
sample size calculation in our small study was based on very large effect sizes, the study might 
not be powered enough to detect smaller effects. 
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Figure 1: Consort Flow Diagram of the study 
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Figure 2:  Mean of BMI factor in patients treated with Fennel and placebo before and after intervention. 
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Table 1. Rotterdam diagnostic criteria for PCOS 
Rotterdam (2003) Diagnostic criteria for PCOS - two out of three of the 
following: 
Clinical Hyperandrogenism (Ferriman-Gallwey Score >8) or 
Biochemical Hyperandrogenism (Elevated Total/Free Testosterone)  
Oligomenorrhea (Less Than 6-9 Menses per Year) or Oligo-Ovulation  
Polycystic Ovaries on Ultrasound (>= 12 Antral Follicles in One Ovary 
or Ovarian Volume >= 10 cm3) 
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Table 2: Mean, standard deviation and p. values of Ferriman-Gallwey values in patients treated with Fennel and 
placebo before and after intervention. 
P. value* Placebo group 
Mean ± SD 
 
pgrrg lenneF 
Mean ± SD 
 
 Variable 
Area  
0.591 2.43 ± 1.40 2.07 ± 1.67 Before intervention  Chin 
0.505 1.93 ± 1.59 1.53 ± 1.41 After intervention 
0.331 0.21 ± 0.58 0.8 ± 1.32 Before intervention  Upper lip 
0.377 0.21 ± 0.58 0.67 ± 1.23 After intervention 
0.093 0.93 ± 1.00 2.00 ± 1.77 Before intervention  Chest 
0.533 1.14 ± 1.35 1.47 ± 1.41 After intervention 
0.505 1.07 ± 1.54 1.53 ± 1.77 Before intervention  Upper abdominal 
0.310 0.86 ± 1.46 1.47 ± 1.60 After intervention 
0.201 0.93 ± 1.54 1.73 ± 1.62 Before intervention  lower abdominal 
0.813 1.21 ± 1.63 1.27 ± 1.53 After intervention 
0.813 0.43 ± 1.16 0.60 ± 1.30 Before intervention  Upper back 
0.561 0.14 ± 0.53 0.47±1.13 After intervention 
0.377 0.00 ± 0.00 0.53 ± 1.13 Before intervention  Lower back 
0.377 0.00 ± 0.00 0.20 ± 0.41 After intervention 
0.780 0.00 ± 0.00 0.27 ± 1.03 Before intervention  Upper arm 
0.061 0.00 ± 0.00 0.31 ± 0.35 After intervention 
0.683 0.86 ± 1.46 1.00 ± 1.51 Before intervention  Leg 
0.914 1.00 ± 1.57 0.67 ± 1.11 After intervention 
  
* Mann-Whitney 
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Table 3. Mean, standard deviation and p. values of biochemical factors in patients treated with Fennel and placebo 
before and after intervention. 
Biochemical factors  Fennel group 
Mean ± SD 
 
Placebo 
group 
Mean ± SD 
 
P. value* 
DHEAS (mg/ml) Before intervention  2.94 ± 0.82 2.38 ± 0.89 0.051 
After intervention 7.52 ± 19.48 2.70 ± 1.02 0.813 
 **P. value 0.158 0.490  
Free testostrone 
(pg/ml) 
Before intervention  2.55 ± 1.77 3.85 ± 2.25 0.112 
After intervention 1.76 ± 1.39 2.07 ± 1.59 0.652 
 **P. value 0.136 0.019  
FSH (MIU/ml) Before intervention  5.63 ± 2.20 5.34 ± 2.05 0.715 
After intervention 5.06 ± 2.39 3.91 ± 1.35 0.123 
 **P. value 0.232 0.07  
LH (MIU/ml) Before intervention  10.93 ± 5.83 7.68 ± 3.93 0.186 
After intervention 8.76±3.93 7.57 ± 4.58 0.331 
 **P. value 0.158 0.925  
TSH (MIU/ml) Before intervention  2.01 ± 1.33 1.57±0.87 0.252 
After intervention 2.09 ± 0.90 1.92±0.72 0.505 
 **P. value 0.124 0.583  
Prolactin (mg/ml) Before intervention  18.07±11.74 19.69±7.21 0.451 
After intervention 20.51±14.33 19.05±14.76 0.949 
 **P. value 0.754 0.594  
* Mann-Whitney 
**Wilcoxon  
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Table 4. Mean, standard deviation and p. values of ultrasonographic factors in patients treated with Fennel and 
placebo before and after intervention. 
Ultrasonographic 
factors 
 Fennel group 
Mean ± SD 
 
Placebo 
group 
Mean ± SD 
 
P. value* 
Endometrial 
thickness(mm) 
Before intervention 6.23±1.50 5.46±1.66 0.270 
After intervention 5.81±1.74 5.82±1.81 0.847 
** P. value 0.414 0.609  
Right ovarian 
volume(ml) 
Before intervention 10.30±2.63 9.04±3.26 0.290 
After intervention 8.17±3.32 9.91±3.58 0.123 
** P. value 1.000 0.039  
Left ovarian 
 Volume(ml) 
Before intervention 10.67±3.02 8.73±2.25 0.07 
After intervention 8.26±3.06 8.88±3.08 0.477 
** P. value 0.06 0.655  
Right ovarian 
follicular number 
Before intervention 9.70±2.55 11.86±0.77 0.00 
After intervention 9.06±2.23 11.29±1.20 0.023 
** P. value 0.581 0.145  
Left ovarian 
follicular number 
Before intervention 9.60±2.64 11.93±0.62 0.05 
After intervention 9.47±2.5 11.07±2.5 0.023 
** P. value 0.889 0.459  
* Mann-Whitney 
**Wilcoxon  
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